Clinical Trial Update: REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy [Phase 1]

View source ↗

Summary

Phase 1 trial of REGN7257 in adults with severe aplastic anemia refractory to or relapsed on immunosuppressive therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• REGN7257

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Severe Aplastic Anemia (SAA) | Phase 1 | Status: TERMINATED